全文获取类型
收费全文 | 345篇 |
免费 | 25篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 25篇 |
妇产科学 | 2篇 |
基础医学 | 25篇 |
口腔科学 | 13篇 |
临床医学 | 53篇 |
内科学 | 68篇 |
皮肤病学 | 2篇 |
神经病学 | 17篇 |
特种医学 | 63篇 |
外科学 | 17篇 |
综合类 | 19篇 |
预防医学 | 14篇 |
眼科学 | 14篇 |
药学 | 52篇 |
中国医学 | 1篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 5篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 9篇 |
2013年 | 17篇 |
2012年 | 11篇 |
2011年 | 11篇 |
2010年 | 10篇 |
2009年 | 18篇 |
2008年 | 15篇 |
2007年 | 23篇 |
2006年 | 12篇 |
2005年 | 10篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 7篇 |
2001年 | 9篇 |
2000年 | 2篇 |
1999年 | 15篇 |
1998年 | 13篇 |
1997年 | 17篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 20篇 |
1993年 | 14篇 |
1992年 | 12篇 |
1991年 | 10篇 |
1990年 | 4篇 |
1989年 | 11篇 |
1988年 | 6篇 |
1987年 | 10篇 |
1986年 | 6篇 |
1985年 | 7篇 |
1984年 | 7篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 11篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 5篇 |
排序方式: 共有401条查询结果,搜索用时 15 毫秒
191.
Ⅰ型变态反应是一项重要的健康问题,对Ⅰ型变态反应的正确诊断是危急时刻抢救生命的先决条件.通常,特异性IgE抗体定量检测以及皮肤试验是用于验证医生的临床疑似诊断. 相似文献
192.
193.
Shingo Matsumoto Keita Saito Hironobu Yasui H. Douglas Morris Jeeva P. Munasinghe Martin Lizak Hellmut Merkle Jan Henrik Ardenkjaer‐Larsen Rajani Choudhuri Nallathamby Devasahayam Sankaran Subramanian Alan P. Koretsky James B. Mitchell Murali C. Krishna 《Magnetic resonance in medicine》2013,69(5):1443-1450
The hypoxic nature of tumors results in treatment resistance and poor prognosis. To spare limited oxygen for more crucial pathways, hypoxic cancerous cells suppress mitochondrial oxidative phosphorylation and promote glycolysis for energy production. Thereby, inhibition of glycolysis has the potential to overcome treatment resistance of hypoxic tumors. Here, EPR imaging was used to evaluate oxygen dependent efficacy on hypoxia‐sensitive drug. The small molecule 3‐bromopyruvate blocks glycolysis pathway by inhibiting hypoxia inducible enzymes and enhanced cytotoxicity of 3‐bromopyruvate under hypoxic conditions has been reported in vitro. However, the efficacy of 3‐bromopyruvate was substantially attenuated in hypoxic tumor regions (pO2 < 10 mmHg) in vivo using squamous cell carcinoma (SCCVII)‐bearing mouse model. Metabolic MRI studies using hyperpolarized 13C‐labeled pyruvate showed that monocarboxylate transporter‐1 is the major transporter for pyruvate and the analog 3‐bromopyruvate in SCCVII tumor. The discrepant results between in vitro and in vivo data were attributed to biphasic oxygen dependent expression of monocarboxylate transporter‐1 in vivo. Expression of monocarboxylate transporter‐1 was enhanced in moderately hypoxic (8–15 mmHg) tumor regions but down regulated in severely hypoxic (<5 mmHg) tumor regions. These results emphasize the importance of noninvasive imaging biomarkers to confirm the action of hypoxia‐activated drugs. Magn Reson Med, 2013. © 2012 Wiley Periodicals, Inc. 相似文献
194.
Aweeka FT Rosenkranz SL Segal Y Coombs RW Bardeguez A Thevanayagam L Lizak P Aberg J Watts DH;NIAID AIDS Clinical Trials Group 《AIDS (London, England)》2006,20(14):1833-1841
OBJECTIVES: Zidovudine remains part of combination antiretroviral therapy. Pharmacological studies rely on quantitation of active triphosphates in peripheral blood mononuclear cells. This study evaluated the impact of female sex and contraceptive therapy on zidovudine plasma and intracellular pharmacokinetics and the impact of contraceptive therapy on HIV viral load. METHODS: Serial plasma and intracellular zidovudine pharmacokinetics following oral and intravenous dosing were determined in 18 men and 20 women treated with zidovudine. Women could repeat pharmacokinetics assessment following 2 months oral or injectable contraceptive therapy. Zidovudine plasma and intracellular mono-, di- and triphosphate concentrations were determined by liquid chromatography tandem mass spectrometry. Plasma and cervical viral loads were determined preceding and following 2 months of contraceptive therapy in women. RESULTS: Men exhibited higher area under the concentration versus time curve for intracellular zidovudine and zidovudine-monophosphate following oral and intravenous dosing and higher zidovudine triphosphate following oral dosing. There was no difference between men and women in plasma zidovudine parameters. Furthermore, contraceptive therapy had no effect on zidovudine plasma or intracellular pharmacokinetics or on plasma or cervical HIV-1 RNA levels. CONCLUSIONS: Using an optimized pharmacokinetic design, this study indicated men exhibit significantly higher zidovudine-monophosphate and zidovudine-triphosphate exposure following zidovudine oral administration, having implications for drug toxicity and overall tolerance of zidovudine therapy. The lack of an effect of contraceptive therapy on zidovudine pharmacokinetics is surprising in light of previous pharmacokinetic studies for drugs eliminated primarily through glucuronidation. Contraceptive therapy had no effect on plasma or cervical viral load, results consistent with previous findings. 相似文献
195.
一项丹麦的实验显示,输注去白红细胞的癌症病人比输注去白膜红细胞的癌症病人术后感染并发症更少,但未进行长期研究。已知输血与癌症病人存活率有关已经有几十年时间了。而另一些观察研究则显示,输注大量去白红细胞的病人与输注去白膜红细胞病人相比,其5年存活率仅稍稍高些,原因可能与手术期间进行了免疫抑制治疗有关。本文对那项丹麦实验中输注过去白膜红细胞及去白红细胞的病人采用随机分组法进行了追踪研究。这项丹麦实验于1992~1995年间进行,用于证实输注去白红细胞能否比输注去白膜红细胞减少在结肠直肠术后病人产生感染并发症的风险… 相似文献
196.
JURAJ MELICHERCIK JOHANNES BRACHMANN † WOLFGANG SCHÖLS † THOMAS HILBEL † THORSTEN BEYER † WOLFGANG KÜBLER† 《Pacing and clinical electrophysiology : PACE》1999,22(1):65-72
Experimental and clinical data suggests that almost all Class III antiarrhythmic agents diminish their ability to prolong cardiac repolarization at fast heart rates. However, only limited data exists about the time course of efficacy decay of Class III agents after sudden increase of the heart rate. In the present study, we assessed both rate and time dependent changes of the efficacy of d-sotalol in higher stimulation frequencies following an abrupt increase in heart rate. This might imitate the situation seen in the development of paroxysmal tachycardias. Monophasic action potentials were recorded from the right ventricular apex during sinus rhythm and constant stimulation with the paced cycle length (PCL) of 550 ms, 400 ms, and 330 ms in the baseline and 20 minutes after intravenous administration of d-sotalol (2.5 mg/kg) in seven patients with documented life-threatening ventricular tachyarrhythmias. D-sotalol significantly prolonged monophasic action potential duration at different steady-state heart rates (sinus rhythm: 21.1%± 3.6%; PCL 550 ms: 16.6%± 4.3%, 400 ms: 11.2%± 2.7%, 330 ms: 5.8%± 2.1%). The prolongation is significantly shorter in higher steady-state pacing, confirming a pronounced reverse-use dependent decrease of the efficacy of d-sotalol at faster stimulation frequencies. After the abrupt increase in heart rate, the beat-to-beat adaptation of the postdrug action potential prolongation exhibits only slight reverse-use dependent shortening. The decrease of the efficacy of d-sotalol is insignificant for the first 20 consecutive beats at the stimulation frequency of the PCL of 400 msec (from 16.6% at PCL of 550 ms to 14.6% at the 20th beat of the PCL of 400 ms), and for the first ten consecutive beats at the stimulation frequency of the PCL of 330 ms (from 16.8% at PCL of 550 ms to 12.3% at the 10th beat of the PCL of 330 ms). This slow decay of action potential prolongation after an abrupt increase in heart rate might contribute to the antiarrhythmic action of d-sotalol in cardiac tachyarrhythmias. 相似文献
197.
Predictors of death from chronic graft-versus-host disease after bone marrow transplantation 总被引:4,自引:9,他引:4
Wingard JR; Piantadosi S; Vogelsang GB; Farmer ER; Jabs DA; Levin LS; Beschorner WE; Cahill RA; Miller DF; Harrison D 《Blood》1989,74(4):1428-1435
Chronic graft-v-host disease (chronic GVHD) is a frequent cause of late morbidity and death after bone marrow transplantation (BMT). The actuarial survival after onset of chronic GVHD in 85 patients was 42% (95%Cl = 29%, 54%) at 10 years. Baseline characteristics present at the onset of chronic GVHD (before therapy) in 85 patients were reviewed to determine which were risk factors for death. In a multivariate proportional hazards analysis, three baseline factors emerged as independent predictors of death: progressive presentation (chronic GVHD following acute GVHD without resolution of acute GVHD; hazard ratio of 4.1, 95% Cl = 2.1 to 7.8), lichenoid changes on skin histology (hazard ratio of 2.2, 95% Cl = 1.1 to 4.3), and elevation of serum bilirubin greater than 1.2 mg/dL (hazard ratio = 2.1, 95% Cl = 1.1 to 4.1). Actuarial survival of 23 chronic GVHD patients with none of these risk factors was 70% at 6 years (95% Cl = 38%, 88%). Thirty-eight patients with one of these risk factors had a projected 6-year survival of 43% (95% Cl = 21%, 63%). The 29 patients with any combination of two or more of these factors had a projected 6-year survival of only 20% (95% Cl = 8%, 37%). Identification of baseline risk factors should facilitate design of trials of chronic GVHD therapies and assignment of high-risk patients to more aggressive innovative therapeutic regimens. 相似文献
198.
Interleukin-7 (IL-7) is an important growth factor in B and T lymphopoiesis in mouse and human, whereas IL-7 has been regarded to lack proliferative effects on cells within the myeloid lineage. However, we have recently reported that IL-7 potently can enhance colony stimulating factor (CSF)-induced myelopoiesis from primitive murine hematopoietic progenitors, showing a novel role of IL-7 in early murine myelopoiesis. Using CD34+ human hematopoietic progenitor cells, we show here a similar role of IL-7 in human myelopoiesis, although interesting differences between the two species were found as well. Although purified recombinant human (rh)IL-7 alone did not induce any proliferation of CD34+ cells, IL-7 in a concentration-dependent manner enhanced the colony formation induced by all four CSFs up to threefold. Furthermore, stem cell factor (SCF)-induced granulocyte-macrophage (GM) colony formation was increased fourfold in the presence of IL-7. Single- cell cloning assays showed that these synergistic effects of IL-7 were directly mediated on the targeted progenitors, and that IL-7 increased the number, as well as the size of the colonies formed. Morphological examination showed that IL-7 affected the progeny developed from CD34+ cells stimulated by G-CSF or IL-3, increasing the number of CFU-M (colony forming unit-macrophage) and CFU-granulocyte-macrophage, whereas the number of CFU-granulocyte were unaltered. 相似文献
199.
Grasser FA; Murray PG; Kremmer E; Klein K; Remberger K; Feiden W; Reynolds G; Niedobitek G; Young LS; Mueller-Lantzsch N 《Blood》1994,84(11):3792-3798
Monoclonal antibodies directed against the Epstein-Barr virus nuclear protein 1 (EBNA1) were used to examine conventional paraffin sections from a series of EBV-associated lymphoproliferative disorders by immunohistochemistry. The presence of latent EBV infection in tumor cells was determined by in situ hybridization for the Epstein-Barr virus early RNAs (EBERs). Of those EBER-positive cases a total of 28 of 40 cases of Hodgkin's disease, 3 of 3 cases of Burkitt's lymphoma, and 8 of 8 cases of human immunodeficiency virus-associated cerebral B-cell lymphoma expressed detectable amounts of EBNA1. In the positive cases, expression was confined to the tumor cells. No reactivity was detected in EBV-negative cases of the above tumors or in 8 cases of EBV-negative cases of large cell anaplastic non-Hodgkin lymphoma. This report provides the first unequivocal evidence for the expression of the EBNA1 protein in the tumor cells of Hodgkin's disease and validates an important reagent with which to analyze the role of EBV in various virus-associated malignancies. 相似文献
200.
The FLT3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow progenitor cells in vitro 总被引:19,自引:1,他引:19
The present studies investigated the effects of the recently cloned flt3 ligand (FL) on the in vitro growth and differentiation of primitive and committed subsets of human CD34+ bone marrow (BM) progenitor cells. FL alone was a weak growth stimulator of CD34+ BM cells, but synergistically and directly enhanced colony formation in combination with interleukin (IL) 3, granulocyte colony-stimulating factor (G-CSF), CSF-1, granulocyte macrophage (GM) CSF stem cell factor (SCF), and IL-6. FL and SCF were equally effective in stimulating colony formation in combination with IL-3. However, the tri-factor combination of FL + IL-3 + SCF stimulated 2.3-fold and 2.5-fold more colonies than FL + IL-3 and SCF + IL-3, respectively. These additional recruited progenitors appeared to be predominantly located in a primitive (CD71-) subset of the CD34+ progenitors, as 4.5-fold more colonies were formed by CD34+CD71- cells in response to FL + IL-3 + SCF than to FL + IL-3 or SCF + IL-3. Similar findings were observed in serum-containing and serum-deprived cultures. Whereas FL did not enhance burst-forming unit-erythroid (BFU-E) colony formation of CD34+ BM cells in the presence of serum, a low number of BFU-E colonies were formed in response to FL plus erythropoietin (Epo) under serum-deprived conditions. In addition, FL both in serum-containing and serum-deprived cultures stimulated colony formation of more committed myeloid progenitors in CD34+CD71+ BM cells. Thus, FL potently stimulates the growth of primitive and more committed human BM progenitor cells. 相似文献